ANDA 210346, held by Strides Pharma. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 210346 (Triamcinolone Acetonide), held by Strides Pharma, was first approved by FDA on Feb 11, 2019, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 11, 2019 | Original application | Approved | None posted |
| Triamcinolone Acetonide0.025% · cream;topical | Triamcinolone Acetonide | Discontinued |
| Triamcinolone Acetonide0.1% · cream;topical | Triamcinolone Acetonide | Discontinued |
| Triamcinolone Acetonide0.5% · cream;topical | Triamcinolone Acetonide | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
